In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
about
Neuroimaging in Parkinson disease: from research setting to clinical practice.Molecular imaging biomarkers for dementia with Lewy bodies: an update.2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.PET imaging of amyloid with Florbetapir F 18 and PET imaging of dopamine degeneration with 18F-AV-133 (florbenazine) in patients with Alzheimer's disease and Lewy body disorders.PET/SPECT imaging agents for neurodegenerative diseases.DNA methylation profiling in the thalamus and hippocampus of postnatal malnourished mice, including effects related to long-term potentiation.Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders.β-Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementiaAssessing mild cognitive impairment with amyloid and dopamine terminal molecular imaging.Subtle gait changes in patients with REM sleep behavior disorder.Serotonin and molecular neuroimaging in humans using PET.PET radioligands for the vesicular transporters for monoamines and acetylcholine.¹⁸F-FP-(+)-DTBZ positron emission tomography detection of monoaminergic deficient network in patients with carbon monoxide related parkinsonism.Quantitative analysis of binding sites for 9-fluoropropyl-(+)-dihydrotetrabenazine ([¹⁸F]AV-133) in a MPTP-lesioned PD mouse model.Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies.
P2860
Q30868628-C7EEA237-5F62-4521-ADB5-AA02ACCA62C5Q30881333-6A34318F-DE4C-48AB-9FC1-D10BB991BDF2Q30971403-4895D077-DABF-420F-AD5D-E127ED3BEA76Q33637285-BC4DDB74-44F1-4AF7-B92B-39C48E5FF67BQ34156602-3EA56A23-E924-48AF-90C2-38232A6A0DEEQ35098993-26F1CC76-37E3-41D4-80DD-4FA9A8841AA0Q35910290-6EBAE83D-94F1-410A-AA13-2B7E5369D9DAQ36924335-49C5F052-69E3-4F89-A32B-17233154A969Q37214791-5027548C-861D-4842-8307-13680ED5D90BQ37634895-1DAE0AFE-EF7B-4134-80B8-3750D27D003DQ37938794-AC17882D-6A9E-4947-8DAD-05179D6DB23EQ38166971-E564CFDD-6316-45DE-81ED-C3E61C3EEE46Q48324010-86755E6F-2976-4B38-B835-7EC2E37584DEQ48496264-B02021B7-E8F6-4A4C-A890-37666C9DB1ACQ49987358-F85DC110-47D8-4D18-A4C8-138AA4C976F3
P2860
In vivo assessment of vesicular monoamine transporter type 2 in dementia with lewy bodies and Alzheimer disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
In vivo assessment of vesicula ...... bodies and Alzheimer disease.
@ast
In vivo assessment of vesicula ...... bodies and Alzheimer disease.
@en
In vivo assessment of vesicula ...... bodies and Alzheimer disease.
@nl
type
label
In vivo assessment of vesicula ...... bodies and Alzheimer disease.
@ast
In vivo assessment of vesicula ...... bodies and Alzheimer disease.
@en
In vivo assessment of vesicula ...... bodies and Alzheimer disease.
@nl
prefLabel
In vivo assessment of vesicula ...... bodies and Alzheimer disease.
@ast
In vivo assessment of vesicula ...... bodies and Alzheimer disease.
@en
In vivo assessment of vesicula ...... bodies and Alzheimer disease.
@nl
P2093
P1433
P1476
In vivo assessment of vesicula ...... y bodies and Alzheimer disease
@en
P2093
Christopher C Rowe
Colin L Masters
Daniel M Skovronsky
Gaël Chételat
Graeme O'Keefe
Hank F Kung
Henry Tochon-Danguy
John Drago
Rachel S Mulligan
Svetlana Pejoska
P304
P356
10.1001/ARCHNEUROL.2011.142
P577
2011-07-01T00:00:00Z